MedTrace Logo

Effects of MWM Vs Sustained Mobilization on Knee Osteoarthritis

NCT07315464 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-01-02

No results posted yet for this study

Summary

This article focused on people diagnosed with grade III Knee OA with sample size of 68 patients , who will randomly divided into two groups . Group A received Mulligan's MWM while group B received Kaltenborn's Sustained Mobilization along with eccentric exercises. The goal of the study was to compare the effectiveness of these two treatment conditions in reducing knee pain and improving joint function decreasing disability in daily activities. The patients followed a structured treatment plan over a set period and outcomes will measured using reliable clinical tools such as NPRS for pain KOOS for functional disability and Goniometer for ROM.

Conditions

Interventions

OTHER

mulligan moblization

This group will receive total 3 sessions / week (9-12 sessions) Intensity includes Accessory Glide with pain free active knee motion + moderate intensity eccentric loading Type includes Mulligan MWM ( Passive Glide during active knee flexion/extension + Eccentric Quadricpes Exercises (Slow Controlled Squats ) Time 30-45 mins

OTHER

kaltenborn moblization

This group will receive frequency of 3 session/ week (9-12 sessions) Intensity includes Kaltenborn Grade II Traction according to pain tolerance + Moderate Intensity Eccentric Loading Type of Exercise includes Sustained Joint Mobilization in loose pack position + Quadriceps Exercises (Slow step down ) Time 35-45 mins

Sponsors & Collaborators

  • Lahore University of Biological and Applied Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-30
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07315464 on ClinicalTrials.gov